Study S002272

INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04945070
Acronym: IDEAL
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 96
Start: 2021-07
Primary completion: 2023-01
Lead sponsor: Institute for Clinical and Experimental Medicine
Conditions: Type 2 Diabetes Treated With Insulin
Interventions: DRUG:IGlarLixi; DRUG:MDI - Multiple dose insulin injection
Results posted: FALSE

Registered primary outcomes

HbA1C [6 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004918	The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol. Novodvorský P, Diabetes therapy : research, treatment and education of diabetes and related disorders	2024	Protocol	PMID 38653903 DOI	cites ClinicalTrials.gov:NCT04945070; registry reference DERIVED:38653903